Market Size (2018)
$722.62M
Vertical: HealthcareBase Year: 2018
Market Size (2018)
$722.62M
Projected (2025)
$1.23B
CAGR (2016–2025)
8.1%
Key Players
10+
Primary human cells are isolated directly from normal human tissue or blood cells via the enzymatic or mechanical methods. Primary cells retain their fundamental cellular functions. Hence, their use in cell-based research programs is increasing significantly.
The key factors driving the market growth are growing cancer research across the world, a wide range of applications of primary cells for disease treatment, advantages of primary human cells over cell lines, and growing research and development in biotechnology and biopharmaceutical industries. However, factors such as high cost of advanced primary cells and risk of contamination of primary cells hamper the market growth. The increasing demand for primary cells for research, innovation, and launch of new drugs act as an opportunity for the market.
The Primary Cells Market market is projected to grow at a CAGR of 8.1% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe scope of the global primary cells market study includes the market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on source, type, end user, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global primary cells market is a very lucrative, attractive, and profitable market, both for existing players as well as new entrants. At the same time, intense rivalry among existing competitors has been observed. Our analysis revealed that market players have adopted different strategies to increase their business and position in the global primary cells market.
In recent years, strategic movements made by major players were product launches, acquisitions, and strategic agreements, which have been used as market penetration strategies and to reduce competition. The major players in the global primary cells market are Lonza, STEMCELL Technologies Inc, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biologics, Inc., and others.
Companies are now entering into collaborations, product launches, and expansions to neutralize growing competition from customers, competitors, and to tackle the changing market dynamics.
There are numerous players operating in this market all over the globe. Most of these players exist in the American and European regions. There are a lot of large and small market players available in the market which provide a wide range of products.
Lonza, STEMCELL Technologies Inc, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biologics, Inc., and others are the major players in the global primary cells market, contributing a major share of the total global market.
Threat of New Entrants
The threat of new entrants is moderate in the global primary cell market due to the initial investment cost and the presence of major players. Any company trying to enter the market is required to accept and abide by the mandatory regulatory standards. This market is characterized by different types of products, a reasonable degree of brand loyalty, where establishing a brand name is difficult for new entrants. The growing healthcare industry, market profitability, and research activity encourage new players to enter the market. There is a stronghold of the big companies in this market, which can make the entry of the new players challenging. Thus, the threat of new entrants in the market is moderate in the global primary cell market.
Bargaining Power of Suppliers
In the global primary cell, the suppliers are healthcare companies that manufacture reagents, culture media, and cell cultures. The existing key companies capture a significant share of the market and have the capability of influencing the cost of the products. Another factor affecting the bargaining power of suppliers is the number of buyers and suppliers in the market, as there is large number of buyers in the market, which can increase the demand for the product and supports the bargaining power of suppliers. But the low dependency of buyers on suppliers and the presence of alternative products in the market decreases the bargaining power of suppliers. By considering the above-mentioned factors the bargaining power of suppliers is moderate in the primary cell market.
Threat of Substitutes
The threat of substitutes in the global primary cell market is moderate. The presence of substitutes, such as cell lines, can offer a roughly similar application. The availability of alternative products in the market may increase the threat of substitutes in the primary cell market.
Bargaining Power of Buyers
Pharmaceutical & biotech companies, research centers, and academies are the primary buyers in the market. The presence of a large number of buyers owing to the increasing use of primary cells in the healthcare industry in new drug development supports the bargaining power of buyers. Also, some buyers are price and brand sensitive and might prefer particular products from certain companies, thereby moderately affecting their bargaining power in the market. Thus, the bargaining power of buyers is moderate.
Intensity of Rivalry
The degree of competition in the global primary cell market is moderate to high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Companies involved in the primary cell market are trying to develop different types of products to grow their business. To overcome the competition, players are engaged in developing a process to lower their manufacturing costs. Moreover, the players are also developing advanced manufacturing techniques for differentiating their product from their rivals.
Market estimates by geography (2025)
InsightEurope leads with $420.77M by 2025, while Asia Pacific is projected to grow fastest at a 9.0% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $34.18M | $46.73M | $59.24M | 6.3% | 5% |
| North America | $189.72M | $274.39M | $378.90M | 8.0% | 31% |
| Asia Pacific | $136.74M | $207.67M | $297.31M | 9.0% | 24% |
| Europe | $202.67M | $300.00M | $420.77M | 8.5% | 34% |
| South America | $47.13M | $61.40M | $77.44M | 5.7% | 6% |
| Total | $610.44M | $890.19M | $1.23B | 8.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$1.23B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Human Primary Cells | $872.71M | 8.0% | 71% |
| Animal Primary Cells | $360.95M | 8.5% | 29% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Primary Cells Market covering market dynamics, competitive landscape, and strategic outlook.
The Primary Cells Market market is projected to reach $1.23B by 2025, growing at 8.1% CAGR. The Human Primary Cells segment holds the largest share.
Primary human cells are isolated directly from normal human tissue or blood cells via the enzymatic or mechanical method. Primary cells retain their fundamental cellular functions. Hence, their use in cell-based research programs is increasing significantly.
Numerous factors such as rapid growth in the biotechnology and biopharmaceutical industries, growing cancer research, rising adoption of primary cells over cell lines, increasing demand for monoclonal antibodies, and rising healthcare expenditure are anticipated to drive the growth of the market during the forecast period. Additionally, the growing research on personalized therapies and stem cells is likely to contribute to market growth. However, the high cost of advanced primary cells and risk of contamination may hamper the growth of the market. The increasing preference of primary cells in research and development to develop new drug acts as opportunities for the growth of the primary cell market.
Cancer is one of the major causes of death across the globe and is responsible for a large number of deaths. Different pharmaceutical companies and research institutes are involved in developing cancer treatment drugs using cell culture. The increasing prevalence of cancer across the globe is promoting the demand for research activities to develop new drugs. According to the National Cancer Institute in 2018, around 1,735,350 cases of cancer were diagnosed in the US alone.
Additionally, Cancer Research UK reported that in 2018 the new cases of cancer were reported to be 17 million across the world. The increasing number of populations suffering from cancer increases the demand for new research activities to develop new drugs, which ultimately increases the demand for products such as primary cell culture. For instance, the National Cancer Institute conducts different research on cancer biology, cancer genomics, and causes of cancer using primary cell culture. Additionally, there are different major and small manufacturers and suppliers such as Merck KGaA and PromoCell GmbH, who provide primary cells for cancer research.
In research activity, primary cells are used for drug screening and to study the effect of drugs on human cells. During cancer research the primary cells are exposed to different chemicals, radiations, and can be infected with viruses to make them cancerous. These cells can be used to study the cause of cancer, mechanism, and transformed signaling pathways. They are also used to study the adverse effects of cancer treatments such as chemotherapy and irradiation on normal cells. The increasing prevalence of cancer and research activities to develop new drugs drives the market growth of primary cells.
Research and development activities are growing across the globe due to the increasing number of pharmaceutical and biotech manufacturing units. The primary cell is used in drug screening at the clinical stage, before launching the drug into the market. The increasing focus on genomic research, personalized medicines, and growing research on cancer treatment act as an opportunity for market growth. Increasing use of primary cells in 3D cell culture technology to study cell morphology, cancer cells, and new drug development acts as an opportunity to grow the market in the future.
The increasing number of biobanks to store different types of cells collected from the donor has supported the primary cell market by increasing the availability of human primary cell samples used in research. The increasing number of cell banks across the world drives market growth. The cryopreservation method is also an efficient technique through which the cells can be stored for longer period with similar cell property and can be used whenever required.
Also, increasing funding by the government for research and development activity in pharmaceutical sector supports market growth. For instance, in 2014 governments of Organization for Economic Cooperation and Development (OECD) countries accounted about USD 51 billion on health-related research and development. Thus, improving research and development (R&D) and increasing number of biobanks are expected to be the greatest opportunities for the global primary cell market.
Contamination is the most common problem while working in laboratories using cell culture. Mycoplasma, fungi, yeast, bacteria, chemicals, and laboratory instruments are different sources of contamination in labs, whereas the microbial contamination occurs through poor handling of culture, using nonsterile equipment and instruments. In addition, laboratory facilities such as laminar airflow and humidified incubators are sources for contamination while handling primary cells.
Other factors, such as limited lifetime of primary cells compared to immortalized cell lines may affect the demand for these cells. Additionally, another limitation of primary cells is the procedure to isolate the cells using different chemicals and enzymes. These procedures affect cellular products and damages the integrity of the cell membrane that may affect the quality of the primary cell. The change in the quality of cell hampers the demand for products from researchers.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 106 companies operating in the Primary Cells Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
Lonza is the world's largest and longest-established pure-play contract development and manufacturing organization (CDMO). It sells development, manufacturing and technology services to pharmaceutical and biotechnology companies across the main modalities: - mammalian and microbial biologics; - small-molecule APIs and drug products; - antibody-drug conjugates (ADCs) and bioconjugates; - cell and gene therapies; - mRNA. Following the March 2026 agreement to sell Capsules & Health Ingredients (CHI) to Lone Star Funds, Lonza is completing a two-year transformation into a focused CDMO. It now operates three business platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. Its differentiation rests on four things: - scale, including Visp, Vacaville (the largest US biologics CDMO site) and Portsmouth; - an integrated drug-substance-to-drug-product offering; - a proprietary toolbox: GS Xceed® expression, Ibex®, Synaffix® ADC linkers and the Nona TfR1 BBB technology; - a quality track record across 125+ years of chemical and biological manufacturing. FY2025 continuing sales were CHF 6.5bn at a 31.6% CORE EBITDA margin. Management guides FY2026 to 11–12% CER growth and a 33–34% margin. --- **Company's own description.** In its 2026 releases Lonza calls itself the world's leading CDMO "dedicated to serving the healthcare industry." It describes a team of around 20,000 people working with pharma and biotech customers to turn breakthrough innovations into viable therapies, using science, smart technology and lean manufacturing (H1 2026 release boilerplate). The FY2025 FYR and AR2025 present the business as three complementary, integrated CDMO Business Platforms "powered by the Lonza Engine®." The Lonza Engine is the company's term for its combined strengths in science, smart technology and lean manufacturing for complex and emerging modalities (6 Mar 2026 release). **What Lonza does.** Lonza takes a customer's molecule, from DNA sequence or chemical route, and develops and manufactures it. Work runs from pre-clinical development through clinical supply to commercial launch and lifecycle manufacturing. Revenue comes from four sources: - **Development services.** Cell-line development, process and analytical development, formulation and regulatory CMC. Typically billed fee-for-service or per milestone. - **Clinical and commercial manufacturing.** Drug substance and drug product. Usually batch-based or capacity-reservation contracts, often with take-or-pay or minimum-volume features. Large commercial deals are frequently multi-year and sometimes involve customer co-funding of dedicated capacity, as in the Ibex model and the 2026 Stein ADC line backed by a long-term customer commitment. - **Technology licensing.** GS Xceed® expression system licences, Synaffix ADC technology licences with upfront/milestone/royalty structures, bYlok® and the Nona TfR1 BBB platform. - **Products (Bioscience).** Cell-culture media, primary cells, transfection systems (Nucleofector™), endotoxin and microbial testing. Sold as consumables and instruments. **Revenue-model mix.** Lonza does not publish an exact split between product, service, subscription and licensing revenue. The analyst estimate is that more than 90% of continuing revenue is service-based CDMO revenue (development plus manufacturing). The rest is Bioscience products, reported within Specialized Modalities, and technology licensing. There is no subscription revenue. Licensing is strategically important as a customer-acquisition funnel but financially small; its amount is not separately disclosed. **Value-chain position.** Lonza sits between drug innovators (big pharma, mid-cap and small biotech) and patients. It is an outsourced manufacturer that carries large fixed-asset intensity: - PP&E of CHF 8.3bn at FY2025 (S&P/StockAnalysis); - CapEx of CHF 1.3bn in FY2025, 19.6% of sales (FY2025 FYR). Its upstream suppliers are equipment, single-use consumable, raw-material and media vendors. Downstream, its customers own the regulatory licences and commercialize the drugs. **Customer types:** 1. Large pharmaceutical companies outsourcing commercial capacity. Examples are the strategic multi-site US biopharma collaboration expanded on 1 Jul 2026 and the Vacaville commercial contracts. 2. Mid-size and emerging biotech needing integrated DNA-to-IND and clinical supply. Example: the ImmuneOncia late-stage mAb deal, March 2026. 3. Academic and research customers (Bioscience). 4. Cell and gene therapy developers (autologous and allogeneic). **End-markets.** The main end-markets are: - biologic therapeutics (mAbs, bispecifics, fusion proteins); - ADCs and bioconjugates in oncology; - small-molecule APIs including highly potent APIs (HPAPI); - cell and gene therapy; - microbial-derived proteins, peptides and enzymes; - mRNA/LNP; - research tools. **Analyst characterization.** Lonza is a capital-heavy, scale-advantaged infrastructure provider to biopharma. Its economics depend on asset utilization: - New plants dilute margins during ramp-up. This was visible in FY2023, when the CORE EBITDA margin fell to 29.8%, and in early Vacaville. - Mature, full assets earn returns well above group average. Advanced Synthesis reached a 48.1% CORE EBITDA margin in H1 2026. The CHI exit removes a lower-growth consumer-health and capsule business that lacked CDMO synergy. It turns Lonza into a purer "picks-and-shovels" exposure to biologic and complex-modality pipelines. The key debates are: - the pace of capacity absorption at Vacaville and Visp large-scale; - competitive intensity from Asian CDMOs and big-pharma insourcing; - capital intensity versus free-cash-flow conversion.
STEMCELL Technologies Inc. is a biotech company that offers cell culture and cell separation media used in the research field. These mediums are used in hematology, immunology, neuroscience, stem cell, epithelial cell biology, and mesenchymal cell. STEMCELL Technologies Inc. delivers around 2,500 products to more than 80 countries globally. STEMCELL is the largest biotechnology company in Canada and has offices in eight countries, including the US, UK, Germany, France, Australia, Singapore, and China. Along with the cell culture medium, the company specializes in stem cell detection kits, software, training courses, contract services, and proficiency testing.
PromoCell is a manufacturer of cell culture products and offers a collection of adult stem cells, as well as blood cells from normal human bone marrow, umbilical cord tissue, placenta, adipose tissue, peripheral blood, and cord blood. The company’ s product portfolio also includes high-quality media for these cell types, in addition to optimized differentiation media systems.
Axol Bioscience Ltd manufactures human cell products and critical reagents such as media and growth supplements. The company expertise in reprogramming cells to iPSCs and then differentiating to various cell types. They supply differentiated cells obtained from healthy donors and patients of certain disease backgrounds. In addition to this, they also take primary extract cells provided by customers and then reprogram and differentiate. The company also offers optimized media, coating solutions, and other reagents. Their in-house R&D team works to improve existing media and reagents as well as innovate new products for human cell culture.
American Type Culture Collection (ATCC) is a global biological materials resource and standards organization. It offers a broad range of products and services manufactured under ISO certification and accreditation. The institutes’ offerings include human & animal cell lines, continuous primary, immortalized, and stem cells; cell and microbial derivatives; culture media and reagents; molecular genomic tools; microorganisms; and biological products. ATCC researches to improve the preservation, propagation, classification, and characterization of cultures and to develop new & enhanced culture products through in-house efforts & collaborative alliances
AllCells provides high quality human primary blood and marrow-based cells from the last 21 years. The company's line of business includes the production of bacterial and virus vaccines, toxoids, and analogous products. It is a leading biotechnology company dedicated to providing researchers and biomanufacturing organizations with high-quality primary cells that enable preclinical development, drug discovery, and manufacturing of cell therapies. The company maintains a large repository of donor profiles that can be qualified for various biomedical applications. AllCells is based in Alameda, California, USA
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)